Apr 30, 2018

Diplomat Launches CastiaRx, Industry-Leading Specialty Benefit Manager

FLINT, Mich. — April 30, 2018 — The nation’s largest independent provider of specialty pharmacy services unites benefit-management companies to form specialty-focused CastiaRx.

Diplomat Pharmacy, Inc. (NYSE: DPLO), has unveiled CastiaRx to respond to industry demand for a leader in specialty benefit management.

CastiaRx unites the full-service pharmacy benefit manager (PBM) capabilities of recently acquired LDI Integrated Pharmacy Services and National Pharmaceutical Services with Diplomat’s specialty pharmacy and infusion expertise.

According to the the IQVIA Institute for Human Data Science, the late-phase development pipeline recently included more than 800 specialty drugs. The Pharmacy Benefit Management Instituteprojects that more than 50 percent of U.S. drug spend will be specialty by 2020.

Albert Thigpen, president and chief operating officer of CastiaRx, said specialty drugs are life-changing for people with complex diseases—including cancer and rare genetic conditions—but often require more expert support.

“The current PBM model wasn’t designed to address the challenges that come with specialty drugs,” Thigpen said. “While CastiaRx offers traditional PBM services, we also bring broader depth to address the intricacies of specialty pharmacy management—under both the pharmacy and medical benefit. With 24/7 patient support, advanced analytic capabilities, and clinical expertise founded on a centers-of-excellence approach, we can help patients achieve the best possible outcomes.”

Joel Saban, president of Diplomat, said CastiaRx simplifies the patient journey by tailoring support based on the patient’s stage of illness, clinical status, and communication preferences. He said the brand focuses on anticipating member needs, increasing adherence, closing gaps in care, and ultimately enabling better outcomes. CastiaRx offers a range of service levels, with high-touch support for patients who need it and digital tools for those who prefer self-service.

“Managing specialty drug spend is part of our company’s DNA,” Saban said. “We saw tremendous synergies between Diplomat’s longstanding efforts in this area and those of our PBMs. Uniting all this under CastiaRx can relieve the complexity of specialty drug management for small and midsize payers as we provide a true solution to help them prepare for what’s ahead.”

CastiaRx combines 50 years of PBM service with more than 40 years’ experience handling specialty pharmaceuticals.

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance and may include Diplomat’s expectations regarding benefits of business and growth strategies. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include: our ability to adapt to changes or trends within the specialty pharmacy industry; increasing consolidation in the healthcare industry; our ability to successfully integrate acquired businesses; and the additional factors set forth in “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2017, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payers, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

About CastiaRx

CastiaRx is the industry’s leading specialty benefit manager. Combining full-service pharmacy benefit manager capabilities with specialty expertise, CastiaRx addresses spend across the benefit spectrum. The company leads with compassion, striving to simplify specialty management for its partners. Believe in better with CastiaRx—better treatment, better care, and a better path to a healthier future. For more information, visit castiarx.com.

### 

Market Buzz

Jul 12, 2018 Acentrus Specialty Partners with CPPA for Specialty Pharmacy Practice Accreditat...
Jul 12, 2018 Letco Medical, L.L.C. Acquired by Current Management Team
Jul 10, 2018 Lorrie A. Carr Appointed as CEO for Excelera
Jul 02, 2018 Medi-Dose, Inc. / EPS, Inc. Announces New Packaging Option for its Steri-Dropper...
Jun 26, 2018 Effective June 26, R.J. Hedges & Associates will be offering their comprehensive...
Jun 25, 2018 Medical Packaging Inc. Named One of The Best Places to Work In New Jersey
Jun 20, 2018 Prudential Overall Supply a Clean Green Certified Company Releases Clean Green V...
Jun 15, 2018 Retail Management Solutions named in the top 250 of the Fifty Five and Five Inbo...
Jun 14, 2018 Tutela Welcomes Fertility Specialists Medical Group (FSMG) and The San Diego Cen...
Jun 11, 2018 SuiteRx Saves the day at APPA's 2nd Annual PharmaCon Expo
Jun 11, 2018 CPS Telepharmacy’s New Innovation Center Built to Meet Growing Technology Dema...
Jun 08, 2018 SuiteRx is Attending the 2nd Annual PharmaCon Expo in Orlando, Florida this week...
Jun 08, 2018 Worldwide Business with kathy ireland® Explores Infection Prevention with Analy...
Jun 04, 2018 FDS, Inc. Announces New CEO
May 25, 2018 Excelera Members Benefit from Accreditation Measure Validation Services Provided...
May 11, 2018 Sentara RMH Medical Center Partners with Omnicell to Enhance Efficiency, Safety ...
May 11, 2018 Medi-Dose, Inc. / EPS, Inc. Announces Auxiliary Labels for Neuromuscular Blockin...
May 09, 2018 Jamco First to Achieve Updated FM Approvals
May 03, 2018 CriticalPoint Peer Network
May 01, 2018 Contec, Inc. Acquires Building in Spartanburg County Industrial Park
May 01, 2018 SynMed® ULTRA now installed in the US
Apr 30, 2018 Diplomat Launches CastiaRx, Industry-Leading Specialty Benefit Manager
Apr 30, 2018 RXinsider is proud to present The Compliance Team as a Thought Leader in Exempla...
Apr 23, 2018 Lewis Drug Awarded Exemplary Provider® Accreditation
Apr 17, 2018 25% OFF Pharmacy Software License Fee
Apr 04, 2018 TCGRx Announces the Acquisition Of ARxIUM’S Panasonic Fastpak Exp and Fastpak ...
Apr 04, 2018 Fagron Strengthens Strategic Position in USA Through Highly Complementary Acquis...
Mar 30, 2018 KeyCentrix appoints Luis Rodriguez as President
Mar 27, 2018 iMedicare Rebrands to Amplicare, a Decision-Automation Platform that Enables Hea...
Mar 27, 2018 Mercyhealth Adopts Omnicell’s XR2 Automated Central Pharmacy System to Enhance...

RXinsider Product Overview Videos